Tafinlar Европска Унија - Исландски - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - melanoma - Æxlishemjandi lyf - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. viðbótar meðferð melanomadabrafenib ásamt trametinib er ætlað til viðbótar meðferð fullorðinn sjúklinga með stigi iii húðkrabbanum með meÐferÐ v600 stökkbreyting, eftir fylltu brottnám. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Braftovi Европска Унија - Исландски - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Æxlishemjandi lyf - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Mektovi Европска Унија - Исландски - EMA (European Medicines Agency)

mektovi

pierre fabre medicament - binimetinib - melanoma - Æxlishemjandi lyf - binimetinib ásamt encorafenib er ætlað fyrir meðferð fullorðinn sjúklinga með unresectable eða sjúklingum húðkrabbanum með meÐferÐ v600 stökkbreytingu.